TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets
D361FC00001
Phase 2 small_molecule active
Quick answer
TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active